

# CHECKPOINT TRENDS LIMITED

Formerly known as Rubra Medicaments Limited

**Reg. Office:** 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

**Email ID:** rubraltd@gmail.com | Website: www.rubramed.com

**CIN:** L74110MH1991PLC326598 | Tel: +91 9167469649

---

May 25, 2024

To,  
BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai – 400 001

**Scrip Code** : 531099  
**Sub** : Outcome of Board Meeting

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Saturday, May 25, 2024, inter alia, has considered and approved the following:

1. Audited Standalone Financial Results for the year ended March 31, 2024
  - a. Asset liability statement,
  - b. Cash Flow Statement,
  - c. Audit Report thereon.
  - d. Declaration for unqualified report
2. Related Party Transactions pursuant to Regulation 23(9) of SEBI (LODR), 2015 for the year ended March 31, 2025.
3. Cessation of Mr. Sunil Khandalwal as Managing Director of the Company due to the expiry of tenure.
4. Re-appointment of Gopal Kumar Sahu as Independent Director of the Company for a period of 5 years subject to the approval of the shareholders in the ensuing General Meeting of the Company.
5. Reappointment of MNB & Co. LLP as Secretarial Auditor for a period of 3 years from F.Y 2024-2025 upto F.Y 2026-2027

**The meeting commenced at 11.30 A.M. and concluded at 02.45 P.M.**

# **CHECKPOINT TRENDS LIMITED**

**Formerly known as Rubra Medicaments Limited**

**Reg. Office:** 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

**Email ID:** rubraltd@gmail.com | **Website:** www.rubramed.com

**CIN:** L74110MH1991PLC326598 | **Tel:** +91 9167469649

---

Also, pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Trading Window for dealing in securities of the Company by all the Designated Persons and their immediate relatives will be opened from Tuesday, May 28, 2024 onwards.

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

**For CHECKPOINT TRENDS LIMITED**

**Formerly known as Rubra Medicaments Limited**

**Abha Kapoor**

**Director (Finance) and CFO**

**DIN – 02799429**

**CHECKPOINT TRENDS LIMITED**  
(Formerly known as Rubra Medicaments Limited)

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2024

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3	Figures for	Figures for	Figures for	Figures for
		months ended	preceeding 3	corresponding 3	current period	previous period
		31-Mar-24	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	47.00	17.00	8.00	113.00	116.02
II	Other Income	0.00	0.09	0.00	0.09	0.16
III	<b>Total Income (I + II)</b>	<b>47.00</b>	<b>17.09</b>	<b>8.00</b>	<b>113.09</b>	<b>116.18</b>
IV	<b>Expenses:</b>					
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	0.00	0.00	0.00	0.00
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	38.12	3.51	14.30	49.96	35.36
	Finance Costs	0.01	0.00	0.01	0.01	0.01
	Depreciation & amortisation expense	0.19	0.18	0.16	0.69	0.29
	Other Expenses	32.54	7.70	4.88	60.18	88.59
	<b>Total Expenses (IV)</b>	<b>70.86</b>	<b>11.39</b>	<b>19.35</b>	<b>110.84</b>	<b>124.25</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>-23.86</b>	<b>5.70</b>	<b>-11.35</b>	<b>2.25</b>	<b>-8.07</b>
VI	Exceptional Items	0.00	0.00	-0.09	0.00	0.00
VII	<b>Profit / (loss) before tax (V-VI)</b>	<b>-23.86</b>	<b>5.70</b>	<b>-11.44</b>	<b>2.25</b>	<b>-8.07</b>
VIII	Tax Expense:					
	(1) Current tax	0.00	0.00	-1.01	0.00	-0.22
	(2) Deferred tax	-0.71	0.00	0.00	-0.77	0.00
IX	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-23.15</b>	<b>5.70</b>	<b>-10.43</b>	<b>3.02</b>	<b>-7.85</b>
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XII	<b>Profit/(loss) from Discontinuing operations (after tax )(X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>-23.15</b>	<b>5.70</b>	<b>-10.43</b>	<b>3.02</b>	<b>-7.85</b>
XIV	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-23.15	5.70	-10.43	3.02	-7.85
XVI	Earnings per equity share (for continuing operation):					
	(1) Basic	0.00	0.10	0.00	0.06	0.00
	(2) Diluted	0.00	0.10	0.00	0.06	0.00
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic					
	(2) Diluted	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):					
	(1) Basic	0.00	0.10	0.00	0.06	0.00
	(2) Diluted	0.00	0.10	0.00	0.06	0.00
1	<b>NOTES:</b>					
2	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.					
3	The Segment - wise details are not applicable to the Company as the Company has only one segments.					
	Previous period's figures have been reclassified / regrouped, wherever necessary.					

For Checkpoint Trends Limited  
(Formerly known as Rubra Medicaments Limited)



Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429

Place: Mumbai  
Date:- May 25, 2024

**CHECKPOINT TRENDS LIMITED**  
(Formerly known as Rubra Medicaments Limited)

(Rs. in Lakhs)

	Particulars	Figures as at the end of current reporting period	Figures as at the end of the previous reporting period
		31-Mar-24	31-Mar-23
		Audited	Audited
	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	6.75	6.07
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	-	-
	(i) Deferred tax assets (net)	0.74	-
	(j) Other non-current assets	-	-
	<b>Total non-current assets</b>	<b>7.49</b>	<b>6.07</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	70.73	43.03
	(iii) Cash and cash equivalents	1.27	2.22
	(iv) Bank balances other than (iii) above	0.10	0.77
	(v) Loans	11.50	11.50
	(vi) Others to be specified	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	2.26	2.34
	<b>Total current assets</b>	<b>85.86</b>	<b>59.86</b>
	<b>Total assets</b>	<b>93.35</b>	<b>65.93</b>
<b>1</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-493.55	-496.58
	<b>Total equity</b>	<b>53.28</b>	<b>50.25</b>
	<b>LIABILITIES</b>		
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	-	0.04
	(d) Other non-current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>-</b>	<b>0.04</b>
	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	14.74
	(ii) Trade payables	0.12	0.12
	(iii) Other financial liabilities (other than those specified in item (a))	-	-
	(b) Other current liabilities	-	-
	(c) Provisions, current	39.95	0.78
	(d) Current tax liabilities (Net)	-	-
	<b>Total current liabilities</b>	<b>40.07</b>	<b>15.64</b>
	<b>Total liabilities</b>	<b>40.07</b>	<b>15.68</b>
	<b>Total Equity and Liabilities</b>	<b>93.35</b>	<b>65.93</b>

For Checkpoint Trends Limited  
(Formerly known as Rubra Medicaments Limited)

Place: Mumbai  
Date:- May 25, 2024

  
Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429

**CHECKPOINT TRENDS LIMITED**  
(Formerly known as Rubra Medicaments Limited)

**CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2024**

	Particulars	March 31, 2024	March 31, 2023
		In Lakh	In Lakh
<b>A</b>	<b>Cash Flow From Operating Activities</b>		
	Net Profit before tax and Extraordinary Items	2.24	-8.07
	<b>Adjustment for :</b>		
	Depreciation	0.70	0.29
	Operating Profit before working Capital Changes	2.94	-7.78
	<b>Adjustment for Capital Changes:</b>		
	Increase/Decrease in Current Liabilities & Provisions	24.44	-10.97
	Increase/Decrease in Trade Payables	(0.00)	0.06
	Increase/Decrease in Fixed Assets	-1.39	-5.15
	Increase/Decrease in Cash Loans and advances	0.08	1.40
	Increase/Decrease in Trade Receivables	-27.70	23.60
	Cash Generated From Operations	<b>-1.63</b>	<b>1.16</b>
	Income Tax / Deferred Tax Paid	0.00	-0.21
	Extraordinary items	0.00	0.00
	<b>Net cash from Operating Activities</b>	<b>-1.63</b>	<b>1.37</b>
<b>B</b>	<b>Net Cash From Investing Activities</b>	-	-
<b>C</b>	<b>Net Cash Flow From Financing Activities</b>	-	-
	Net Increase (Decrease) in cash & cash equivalents (A+B+C)	<b>-1.63</b>	<b>1.37</b>
	Opening Balance of Cash & Cash Equivalents	3.00	1.63
	Closing Balance of Cash & Cash Equivalents	1.37	3.00

0.00 0.00

As per our Report of even date.

**For and on behalf of Board of Directors**  
**Checkpoint Trends Limited**  
(Formerly known as Rubra Medicaments Limited)



**Abha Kapoor**  
**Director (Finance) & CFO**  
**DIN: 02799429**

Mumbai  
Date:- May 25, 2024

**Auditor's Report on Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**INDEPENDENT AUDITOR'S REPORT**

To  
The Board of Directors  
**Checkpoint Trends Limited**  
(Formerly known as Rubra Medicaments Limited)

**Opinion**

We have audited the accompanying standalone quarter and year ended financial results of **Checkpoint Trends Limited** (Formerly known as Rubra Medicaments Limited) (the company) for the quarter and the year ended March 31, 2024, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- I. Are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- II. Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and the year ended March 31, 2024.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our opinion is not modified in respect of this matter.





**Management's Responsibilities for the Standalone Financial Results**

These quarter and year ended standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.







# **CHECKPOINT TRENDS LIMITED**

**Formerly known as Rubra Medicaments Limited**

**Reg. Office:** 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

**Email ID:** rubraltd@gmail.com | **Website:** www.rubramed.com

**CIN:** L74110MH1991PLC326598 | **Tel:** +91 9167469649

---

May 25, 2024

To,  
BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai – 400 001

**Scrip Code** : 531099  
**Sub** : Declaration on the Independent Auditors' Report with unmodified opinion pursuant to Regulation 33 (3)(d) of the SEBI (LODR) Regulations, 2015

## **DECLARATION**

I, Abha Kapoor, Director (Finance) & CFO of the Company hereby declare that, the Statutory Auditors of the Company have issued an Independent Audit Report with unmodified/unqualified opinion on Annual Audited Standalone Financial Results of the Company for the year ended March 31, 2024.

**For CHECKPOINT TRENDS LIMITED**  
**Formerly known as Rubra Medicaments Limited**

**Abha Kapoor**  
**Director (Finance) & CFO**  
**DIN - 02799429**